{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040100","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.160993+00:00","generated_at":"2026-06-08T07:04:48.045155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end","bullets":["Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.","Cash and cash equivalents $1.5M as of Sep 30, 2023, down from $3.8M at June 30; post-quarter raised $1.7M in convertible notes.","R&D expenses fell to $1.9M from $4.8M; G&A expenses fell to $1.2M from $1.7M.","PF614-201 time-of-onset study results expected in December 2023; FDA End of Phase 2 meeting set for Jan 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040100","json":"https://secwatch.observer/filing/0001493152-23-040100.json","markdown":"https://secwatch.observer/filing/0001493152-23-040100.md","text":"https://secwatch.observer/filing/0001493152-23-040100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/0001493152-23-040100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:04:48.045155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}